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TREATMENT RESPONSE USING CT-BASED RIGIDITY 
ANALYSIS IN AN ANIMAL MODEL OF LYTIC 
MUSCULOSKELETAL LESIONS SUBJECTED TO SYSTEMIC THERAPY 
PETER JOHN BIGGANE 
ABSTRACT 
 Cancer is a global epidemic; over 1.5 million new cancer diagnoses and greater 
than 600,000 deaths due to cancer are estimated to occur in the United States within the 
year 2015 alone. Approximately two-thirds of patients with bone metastases will 
experience pain, pathological fractures, spinal cord or nerve root compression, paralysis, 
impaired mobility, bone marrow infiltration and hypercalcemia of malignancy. We 
induced bone metastases through inoculation of rat femurs with MDA-MB-231 human 
breast cancer cells in order to compare the effectiveness of various treatment 
modalities, disease progression, and recovery through the use of imaging methods 
in current clinical practice. CTRA provides highly accurate monitoring of metastases 
progression and treatment through both Ibandronate and Paclitaxel therapies. 
Using computed tomography (QCT)-based analysis to calculate the load bearing capacity 
of bone infiltrated with metastatic breast carcinoma, fracture risk threshold was predicted 
using Computed Topography Rigidity Analysis (CTRA) with 100% sensitivity and 90% 
specificity. The results of this study further validate that there is an existing gap between 
clinical guidelines and physician’s recommendations. This inconsistency necessitates that 
the decision-making process for the selection of surgical or non-surgical treatment must 
be narrowed by more advanced prognostic tools such as CTRA.  
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INTRODUCTION 
 
Clinical Problem: 
 Cancer is a global epidemic; over 1.5 million new cancer diagnoses and greater 
than 600,000 deaths due to cancer are estimated to occur in the United States within the 
year 2015 alone(1). Cancer is the second leading cause of death behind heart disease (1) 
and is estimated to surpass heart disease in the near future. Although deaths resulting 
from cancer have been on the decline over the past two decades, the incidence of cancer 
has only slightly decreased in men while remaining stable amongst women (1). One in 8 
women diagnosed with breast cancer (BrCa) will undergo metastasis, and nearly half of 
these metastases will occur in bone.  Approximately two-thirds of patients with bone 
metastases will experience pain, pathological fractures, spinal cord or nerve root 
compression, paralysis, impaired mobility, bone marrow infiltration and hypercalcemia of 
malignancy (2). Advances in treatment regimens have been shown to prolong the lives of 
those affected with BrCa and increase the quality of life through decreased pain and 
greater mobility; however, vertebral fractures continue to be of primary concern. To 
guide treatment modalities and evaluate disease progression once metastasis occurs, rapid 
and accurate analysis of structural changes in bone are necessary, especially when 
surgical fixation is under consideration. 
 Structural rigidity represents the ability of bone to resist deformation, determined 
by the product of the Bone Tissue Modulus (BTM) and the cross-sectional geometry. 
Load bearing capacity (LBC) is a representation of the geometric and material properties 
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of bone and is used to reflect the changes that have occured in the bone’s structural 
rigidity when an osteolytic lesion(s) is present. Both of these are critical elements 
contribute to the bone’s structural rigidity (3) and must be taken into account when 
evaluating the extent to which an osteolytic lesion has influenced the mechanical 
behavior of host bone. This lesion becomes the weakest cross section of bone, causing a 
reduction in LBC and increasing the risk of bone failure and fracture. In the past, 
physicians have utilized two-dimensional radiographs for predicting fracture risk 
secondary to osteolytic lesions to determine the LBC of bone; however, using this 
approach to determine the fracture risk for a three-dimensional object such as bone, only 
takes geometry into consideration and fails to evaluate the changes that have occurred in 
the material properties of the bone. The use of two-dimensional X-rays to determine 
fracture risk is inaccurate (4) and may lead to unnecessary surgical interventions that can 
further compromise patient health and recovery.  
 Rigidity, the structural property that measures the resistance of bone to 
deformation under axial compression, bending or torsional loading, combines both the 
material and geometric properties of bone into a single variable (5). Axial compression, 
bending, and torsional rigidities measured non-invasively on sequential trans-axial 
quantitative computed tomography (QCT) images throughout bone may be used to 
identify progressive changes in bone structural properties. Fracture load and location can 
then be predicted by the cross-section calculated to have the minimum rigidity.  
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Through the use of composite beam theory and serial transaxial CT images, one can 
determine the structural rigidity of bone and, in turn, predict the fracture risk threshold. 
This noninvasive three-dimensional (3D) approach to predicting whole bone fracture risk 
takes into consideration the location and geometry of the osteolytic lesions, as well as the 
biologic activity of the neoplasm and the material properties of bone. This process is 
known as CT-based Structural Rigidity Analysis (CTRA). The use of CTRA has 
demonstrated 100% sensitivity and 90% specificity (6)when evaluating the reduction in 
structural rigidity to predict femur fracture resulting from metastatic lesions. Accurate 
analysis of structural rigidity may allow physicians to have greater confidence in the 
diagnosis of fracture risk and continued monitoring of treatment, leading to more 
efficacious prevention and treatment plans. 
 
Project Aim: 
 Biological up-regulation or down-regulation of normal bone remodeling due to 
skeletal pathologies can result in changes in the quality (lamellar organization and 
mineralization) and quantity of bone. If these changes in bone material and structure can 
reflect the interaction of metastatic tumors with bone, then its mechanical properties 
could be used to monitor the effects of these modulators of tumor growth contributing to 
the degree of deterioration of bone structure. Previously completed components of this 
project have successfully shown, in a series of ex-vivo (4, 7) and in-vivo (8, 9) 
experiments, that the reduction in the LBC of bone with metastatic tumor can be 
predicted non-invasively. Using computed tomography (QCT)-based analysis to calculate 
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the LBC of vertebrae infiltrated with metastatic breast carcinoma, the occurrence of a 
new vertebral fracture was predicted with 100% sensitivity and 90% specificity (6). 
These results are in contrast to the best available fracture risk criteria based on lesion size 
and location on spine CT images (10), which were only 22% specific (11). 
 The aims of the project are 1) to examine the sensitivity of changes in bone 
structural properties measured by CT to the progression of an osteolytic tumor, and 2) to 
demonstrate that QCT-based structural analysis can be used to monitor the 
progression/regression of an osteolytic lesion in response to therapy. This thesis examines 
the ability of QCT to monitor lesion response to therapy. The rats will be assigned into 
one of four groups: (1) Control; (2) Cancer; (3) Paclitaxel; and (4) Ibandronate. As this 
project is still underway, the data subset presented here is the only data available to date. 
Data from larger sample sizes of each treatment group are expected to be available within 
the next few months. 
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BACKGROUND 
Bone Biology:  
 Bone is a dynamic organ consisting of a composite structure of ceramic and 
polymer substances. Dynamic and interactive, bone is constantly remodeling once 
formed, communicating internally and externally to achieve homeostasis.  Unlike 
cartilage, bone is a highly vascular connective tissue that has an integrative role within all 
organ systems of the body. Bone performs six essential functions including structural 
support, locomotion, protection, electrolyte balance, acid-base balance and 
hematopoiesis. The axial and appendicular skeleton provide structural rigidity that 
affords mobility through the attachment of tendons and muscles. The skull and rib cage 
protect otherwise vulnerable organs against moderate external forces. Osseous tissue 
maintains electrolyte balance through storage and release of calcium and phosphate ions 
into the surrounding medullary canal. Regulatory systems within bone prevent acidotic 
and alkalotic states by providing the necessary buffer system to maintain the proper pH 
concentration within the blood through the release and absorption of alkaline phosphate 
and carbonate salts.  Osseous tissue undergoes mineralization to afford bone structure and 
rigidity.  This tissue forms the boundaries of the medullary canal, which protects and 
provides nourishment for hematopoiesis and acts as a reservoir for cytokines and growth 
factors (12).   
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Macroscopic Anatomy of Bone: 
 Primary bone is immature bone and includes woven bone, found in fetal 
development, fracture repair, and osseous tissue turnover. Ultimately, primary bone is 
replaced by secondary bone.  Secondary bone is mature (adult) bone, represented by 
either cortical (lamellar) or trabecular (irregularly arranged lamellar) bone. These two 
distinct types of osseous tissue provide different, yet critical, supportive and metabolic 
functions. There are four generalized shapes of bone; flat, short, long and irregular. Flat 
bones are found within the pelvis, ribs, scapulae, sternum, and mandible. The short-long 
bones make up the carpals, tarsals, patellae, sesamoid bones and appendicular skeleton, 
respectively.  The coccyx, hyoid, vertebrae, and sacrum are comprised of irregular bone. 
The structure of long bone [Figure 1] consists of a hollow shaft (diaphysis) at the center 
leading to the metaphysis and the epiphysis (most distal) at both ends. Growth plates 
represent a line of demarcation between the metaphysis and epiphysis, separating the 
dense cortical diaphysis from the more porous trabecular bone comprising the epiphysis 
and metaphysis. The diaphysis is primarily cortical bone, found in the lateral margins of 
the diaphysis and covered externally by a fibrous periosteum and internally by a fibrous 
endosteum. Approximately 80% of all adult bone is cortical bone; this bone bears the 
brunt of uniaxial, bending and torsional mechanical loading while providing protection, 
musculoskeletal attachment, calcium exchange and structural support.  In the adult, the 
inner diameter of cortical bone establishes boundaries of the medullary canal, which 
contain adipocyte storage, a site previously containing red marrow during the growth and 
development stages. A mesh-like matrix of trabecular bone exists within the medullary 
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canal and accounts for approximately 20% of all bone. The primary site of hematopoiesis 
in the hemodynamic adult occurs within the trabecular bone. The unique alignment of 
trabeculae allows an increased load bearing capacity for the head and greater trochanter 
of long bones, and undergoes a higher turnover rate in contrast to cortical bone. The 
porous nature of trabecular bone lends itself to fracture more readily than the cortical 
bone of the diaphysis. The thoracic and lumbar spine has an approximate composition of 
75:25 while the hip has a ratio of 50:50, of trabecular to cortical bone, respectively. 
Considering that the most common fractures secondary to osteoporosis are vertebral and 
hip in nature, it makes sense then that trabecular bone possesses a weaker structural 
rigidity than cortical bone. 
 
Figure 1: Anatomy of a long bone. 
A) Regions of a long bone include the two ends (epiphysis), the middle shaft (diaphysis), 
and the developmental zone in between (metaphysis). B) Epiphyseal and metaphyseal 
regions are mostly cancellous bone made of trabecular. The diaphyseal region is a hollow 
cortical tube made of osteonal bone. C) Lamellar bone consists of layers of collagen fiber 
in a preferential orientation. These layers can be organized in a parallel fashion or in 
osteons in which they form concentric circles around blood vessels (Haversian Canals). 
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Microscopic Anatomy of Bone: 
 Two-thirds of bone tissue is organic (primarily type I collagen) matter while the 
latter third is inorganic (hydroxyapatite and water-20%) matter. Hydroxyapatite 
[Ca10(PO4)6(OH)2] is the mineral phase that surrounds collagen fibers. The mineral phase 
also contains glycosaminoglycan and proteoglycan. Protein in bone allows for tensile 
strength through a parallel arrangement of type I collagen fibers within lamellae of 
cortical bone arranged in concentric rings within osteons. Without collagen, the bone 
would be pulverized under average daily load bearing activities. Osteons exist in both 
cortical and trabecular bone, known as Haversian systems and packets, respectively. The 
concentric rings of lamellae located within osteons make up the cylindrical walls of the 
Haversian systems in cortical bone. Strength is obtained in the cortical bone between the 
osteons through the perpendicular arrangement of adjacent lamellae in a manner similar 
to the cross banding architecture of plywood. Between lamellae, lacunae house 
osteocytes that were previously osteoblasts now trapped within the mineral phase 
(hydroxyapatite). Canaliculi house dendritic processes of osteocytes; this allows 
communication and regulation of bone turnover. Central to each Haversian system is the 
Haversian canal that possesses both blood supply and innervation. Rods and plates 
comprise the structure of trabecular bone.  Concentric lamellae exist in trabecular bone 
similar to cortical bone; however, unlike cortical bone the lamellae arrangement exists in 
a semilunar formation (13). In contrast to this preferential organization of collagen in 
cortical bone is an irregular arrangement of collagen fibers in woven bone, resulting in a 
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considerably weaker structure. In contrast to cortical and trabecular bone, rapid and 
random deposition of collagen fibers produces woven bone. 
 Modeling and remodeling of both cortical and trabecular bones involve the 
actions of osteoblasts, osteocytes, and osteoclasts. Bone Lining Cells (BLC) are 
important in bone turnover (remodeling) as well and also act as the bone-blood barrier. 
Type I collagen fiber is the primary organic matter of bone tissue. Osteoblasts serve in 
the process of growth and repair of bone through the deposition of these type I collagen 
fibers. Pluripotent stem cells give rise to mesenchymal stem cells (MSC), known as 
osteoprogenitor cells or pre-osteoblasts, which further differentiate into the mature 
osteoblast. Activation of transcription factors Osterix and CBFA1 (RunX2) and inhibition 
of SOX9 are necessary for the commitment of MSCs to the osteoblast lineage. In addition 
to transcription factors, the canonical Wnt/β-catenin signaling pathway, and its associated 
proteins, Bone Morphogenic Protein (BMP) and Fibroblast Growth Factor (FGF) are 
responsible for directing MSC differentiation into osteoblasts. Once proliferation of the 
preosteoblast is complete, the spindle-shaped precursor is now represented by the mature 
osteoblast as a cuboidal shape on the bone matrix surface. The key to recognizing bone 
growth in action is the high alkaline phosphatase activity at the site of proliferating 
preosteoblasts. Osteoblasts serve to mineralize bone by filling in resorption pits that 
created through the action of the osteoclast cells. Once mineralization is complete, the 
entrapped osteoblasts take up a second role as osteocytes. Osteoblasts have recently been 
demonstrated to play a part in the signaling responsible for bone remodeling through their 
primary cilia (14).  
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 After osteoblasts have become trapped in their calcified matrix, their future holds 
several possibilities including apoptosis (50-70%) (15), differentiation into osteocytes, or 
remaining on the surface of the bone as a bone lining cell. Surrounded by a small space 
known as the lacunae, osteocytes communicate through their long processes between 
other osteocytes, osteoblasts, and bone lining cells through gap junctions. Mechanical 
loading and stress have been hypothesized to be sensed by mechanotransduction through 
these gap junctions and the long processes of osteocytes which in turn convey regulation 
of bone turnover.  
 Osteoclasts are the only cell known to produce bone resorption. Unlike 
osteoblasts and osteocytes, osteoclasts are derived indirectly from the hematopoietic stem 
cell (HSC) instead of the MSC.  HSCs differentiate into mononuclear precursor cells that 
further differentiate into large multinucleated osteoclasts under the direction of both 
NFκB ligand (RANKL) and macrophage-colony stimulating factor (M-CSF). The 
dependent relationship between osteoblasts and osteoclasts is understood through the 
requirement of osteoblasts and bone marrow stromal cells to produce RANKL and M-
CSF (16). Osteoclasts possess structural features that allow adherence to the bone 
through posits and podosomes.  Osteoclasts possess podocytes composed of actin that 
allows tight attachment to bone and podosomes that provide a seal between the osteoclast 
and the bone, giving the osteoclast a ruffled membrane appearance as well as an increase 
in surface area. Bone resorption is achieved through the osteoclastic secretion of 
hydrogen ions by H+-ATPase and Cl- channels which in turn causes the exocytosis of 
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cathepsin K, a proteolytic enzyme. Hydrogen ions act to acidify the mineral composition 
of the bone matrix while cathepsin K degrades the protein structure of the bone matrix. 
Bone Formation, Growth, Modeling, and Remodeling: 
 
Formation (ossification): 
 Intramembranous ossification is one of two methods of bone formation and 
occurs in flat bones through the aggregation of undifferentiated mesenchymal cells in a 
highly vascular environment. Osteoblast differentiation occurs, followed by deposition of 
the collagenous osteoid tissue that forms trabeculae. Further remodeling around the 
trabeculae serves to form lamellar flat bone.  Fracture repair also uses intramembranous 
ossification during primary bone healing that aids in repair by callus formation.  
 Endochondral ossification handles the formation of short and long bones and also 
plays a significant role in the process of secondary healing of bone fractures. 
Endochondral ossification occurs first by the construction of an outline of the desired 
bone made from hyaline cartilage, called the hyaline cartilage model. During fetal 
development, mesenchymal tissue forms this shape of the short-long bone. After 
hypertrophy of the MSCs occurs, the formation of perichondrium surrounding the hyaline 
cartilage model occurs and chondrocytes are produced.  Later, differentiation occurs 
again, resulting in the loss of chondrocytes, conversion of the perichondrium into the 
periosteum and the formation of osteoblasts that later mineralize through secretion of 
calcium phosphate to become osteocytes and cortical bone. With the exception of 
secondary bone healing, endochondral ossification takes place from around the sixth 
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week of fetal development until the second decade of a person’s life and so is far less 
frequent throughout life than intramembranous ossification (17). 
 
 Bone Growth: 
 Bone growth starts at the fetal stage around the 6th week of development and 
persists throughout life. Longitudinal growth occurs at the epiphyseal plates (growth 
plate) that separate the highly trabecular metaphysis and epiphysis from the mostly 
cortical diaphysis. Longitudinal growth leads to an increase in height during growth and 
development. By the end of growth and development, the expanding cartilage becomes a 
calcified matrix, undergoes a remodeling process and is replaced by lamellar bone.  
 
Bone Modeling: 
 In 1892, Wolff proposed the theory of bone remodeling. Wolff suggested that 
healthy bone will adapt in response to the loads placed upon it. Modeling involves the 
reshaping of bone in response to physiologic influences or mechanical forces (18) by the 
process of bone resorption and deposition in a loosely coupled relationship between 
osteoclasts and osteoblasts. Bone modeling is much less common than remodeling. 
However, it occurs throughout life primarily through the appositional growth of the 
periosteum and endosteal resorption of old bone.  
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Bone Remodeling: 
 Bone remodeling begins before birth during fetal development and continues until 
death, serving primarily to replace bone lost to micro damage from normal daily activities 
as well as to maintain mineral homeostasis. On average, 10% of our skeleton is renewed 
annually, a continuous remodeling process that ensures the structural integrity of the 
skeleton. In contrast to bone modeling, bone remodeling occurs through small packets 
known as the bone multicellular unit (BMU) which remodels independently of 
neighboring BMU’s. BMU’s involve the unity of osteoblasts and osteoclasts working 
together in a tightly coupled relationship. The BMU orchestrates the replacement of 
micro damaged bone with new bone in these packets while simultaneously releasing 
minerals into the blood. 
 The addition and subtraction of bone mineral density through the remodeling 
process is vital to the structural integrity of the skeleton. When this cooperative 
relationship fails, a threat to the mechanical behavior will occur. When horizontal 
trabeculae resorption occurs in excess, lateral support of the vertically aligned trabeculae 
is reduced and in effect places increased load bearing upon vertically aligned trabeculae 
and an increased risk of fracture. 
 
Breast Cancer, Metastasis, and the Skeleton: 
 Over 4,500 new cases of cancer are diagnosed daily within the US alone (1), and 
over 62, 290 new cases of BrCa in situ are predicted to be diagnosed within the year 2015 
(1). BrCa accounts for 29% of all new cancer diagnoses amongst women (1), followed by 
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lung, and colorectal cancer. Over 23% of these cancers are projected to become invasive 
within the year 2015 alone [Figure 2], which is of great concern considering metastatic 
lesions are the most common cause of morbidity and mortality in these patients. More 
than half of women who present with invasive BrCa will progress to bone metastasis 
(19). 
 
Figure 2: Probability (%) of developing invasive cancer 
 from the most common primary tumors amongst the female population in 2015 (from 
birth to death). 
 
 The metastasis cascade [Figure 3] involves sequential steps that depend, in part, 
upon evasion of the host’s immune system as well as avoidance of apoptotic signaling 
(20). Local invasion of cells from the primary tumor into the surrounding tissue is the 
first step of metastasis. Next, tumor cells migrate into the blood or lymphatic vessels 
occurs and adhere to distant capillary beds after dissemination. For metastasis to occur, it 
takes less than 0.1% of the primary tumor cells to survive this dissemination process (20). 
 After adhesion and arrest of the cell cycle, these malignant cells extravasate into 
the parenchyma of the organ and undergo proliferation that in turn induces organ 
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angiogenesis, one of the many hallmarks of cancer (21). E-Cadherin and N-Cadherin 
have been shown to play an important role in the cell-to-cell adhesion and cell-to-
mesenchymal adhesion, respectively. The downregulation of E-Cadherin is associated 
with poor prognosis of BrCa due to loss of cell-to-cell adhesion and consequent 
intravasation (22). Upregulation of N-Cadherin is thought to cause stromal cell adhesion 
of BrCa tumor cells which allows invasion into the stroma (23). Of note, bone marrow is 
one of the most metabolically active tissues within the body, making bones especially 
susceptible to the dissemination of tumor cells and subsequent metastasis due to the high 
blood flow within red marrow (24). 
 
Figure 3: Schematic showing the metastatic cascade 
 of breast cancer. Figure from (22). 
 
 In 1889, the “seed and soil” theory of metastasis was proposed by Stephen Paget 
to explain how tumor cells have an affinity for specific target organs. Paget went on to 
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explain that tumor cells (the seed) require the appropriate microenvironment (the soil, 
target organ) for metastasis to occur (25). The preferred destination of metastasis is 
thought to be the result of tumor cells priming the microenvironment through secretion of 
substances, creating a “pre-metastatic niche” (22). The expression of vascular endothelial 
growth factor receptor-1 (VEGFR-1) has been demonstrated to be directly responsible for 
tumor activation and angiogenesis (26). Prior to the arrival of tumor cells within pre-
metastatic lymph nodes, patients with BrCa have been shown to express VEGFR-1-
positive hematopoietic progenitor cell clusters, suggesting that priming of the “pre-
metastatic niche” has occurred, creating the ideal microenvironment for metastasis. (22). 
Specifically, BrCa has shown preferential metastases to organs such as the bone and 
lungs. 
 The preferential metastasis of BrCa to bone is further demonstrated through the 
research of Mueller et al. (27) regarding metastasis destination guidance through 
chemokines and their respective receptors. The attraction of BrCa tumor cells to bone 
marrow occurs through chemotaxis and invasion following pseudopodia formation and 
actin polymerization caused by the expression of chemokine receptor motif CXCR-4 and 
its ligand CXCL-12. The CXCR-4-CXCL-12 receptor-ligand relationship has been 
shown to strengthen the migration of BrCa tumor cells to bone. The expression of CXCL-
12 is commonly found in higher quantities in bone marrow as opposed to lower levels of 
expression in the small intestine, kidneys, brain, skin and skeletal muscle.  
 Bone metastases can present as osteolytic, osteoblastic or a combination of both 
osteolytic/osteoblastic metastases. In either case, bone destruction occurs and may 
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simultaneously occur with bone formation (osteoblastic) (28). Through in vitro studies, 
Elion and Mundy (1978) demonstrated that BrCa tumor cells were able to resorb bone 
independent of osteoclast stimulation (29). However, BrCa tumor cell stimulation of 
osteoclasts have been shown to be the primary driving force behind BrCa tumor cell 
metastases (30). BrCa osteolytic lesions contain a high expression of the protein CCN3. 
Recent finding have proposed three mechanisms that implicate CCN3 in the promotion of 
a microenvironment conducive to BrCa bone metastasis: first it increases the NF-κB 
ligand (RANKL) / osteoprotegerin (OPG) ratio; second, the increased proliferation of 
BrCa cells in bone; and third, it promotes calcium oscillations and translocations of 
nuclear factor of activated T cells c1 (NFATc1), leading to an increase in 
osteoclastogenesis. Overexpression of CCN3 in bone marrow results in the impairment of 
osteoblast differentiation and the resultant rise in the RANKL/ OPG ratio leading to 
osteolytic lesions. CCN3 overexpression has also been shown to stimulate colonization 
and growth of metastatic BrCa cells in bone (30). The ability of CCN3 to foster a more 
suitable environment for metastatic BrCa cells in bone supports Paget’s “seed and soil” 
hypothesis evidenced by the overexpression of CCN3 by BrCa cells and the promotion of 
a resorptive environment for osteolytic metastasis.  
 
Symptoms of Bone Metastasis: 
 Patients with BrCA metastasis to bone have an average life expectancy of 2.1 
years, but it lowers to 1.6 years if the metastases become extraosseous.  During this 
period, patients suffer from a broad range of symptoms that can become debilitating and 
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seriously reduce their quality of life. The most severe complications include pain, 
pathological fracture, spinal cord compression, hypercalcemia (31) and death. 
 Both pain and impaired mobility have been found to occur in 65-70% of all 
metastatic bone cancers (32) with osteolytic lesions as the most common source of 
cancer-related pain (33). In a recent trial by Vassiliou et al. (2007), 80 patients with either 
lytic, mixed, or sclerotic skeletal metastasis were evaluated for pain, BMD, and quality of 
life. Patients with osteolytic lesions were shown to have the strongest negative correlation 
with regards to pain, BMD and quality of life. Osteolytic patients reported the highest 
average pain levels and the lowest average BMD. The mean pain score for lytic patients 
was 8.1 (scale = 0-10, 10 = highest) with a mean BMD of 116.3 +/- 40.4 Hounsfield units 
(HU). These patients also had the highest mean opioid requirements and the lowest mean 
reported quality of life (34). This evidence suggests that patients with osteolytic bone 
lesions with excessive bone resorption experience the greatest suffering and thus need 
prioritized treatment. 
 A pathologic fracture occurs in BrCa patients at the location of skeletal metastasis 
due to the destruction of bone with an increase in fracture risk as time progresses. 
Fracture risk for these patients is even higher when the metastases are confined to the 
skeleton. With the loss of structural integrity, the LBC of bone is compromised which 
presents a risk of impending fracture. Both rib and vertebral collapse are the most 
common pathologic fractures second only to osteoporosis (34).  
 When the patient has progressed to this state, daily tasks such as getting out of 
bed in the morning can produce extreme pain. Load bearing long bones pose the greatest 
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risk for fracture, which correlates with the most significant reduction in quality of life due 
to pain and immobility. The most common location of fracture to in load bearing bones is 
the proximal femur with an estimated 10-20% of skeletal metastasis patients experiencing 
this hardship (34). Accurate prediction of fracture risk in patients affords guidance when 
making treatment decisions thereby providing opportunities to prevent pain and loss of 
mobility before they occur and significantly improving the quality of life for the patient. 
Treatment Options for Metastatic Cancer: 
 Prediction of imminent fracture risk and pain have been the gold standard for the 
accurate guidance of treatment in BrCa patients with skeletal metastasis. Various 
methods exist for the prediction of fracture risk; however, CTRA has been shown to 
provide the most precise determination of actual fracture risk with 100% sensitivity and 
90% specificity. Past methods of fracture prediction have relied on a subjective 
interpretation of two-dimensional radiographs and the Mirels scoring system, which 
provides less than 35% specificity. Regardless of the prediction method used, treatment 
options become limited once BrCa tumor cells have metastasized to bone. Treatment 
methods commonly include surgery, chemo- and radiotherapy, bisphosphonates, and 
hormone replacement therapy. Besides treating the disease, treatment is necessary to 
combat the side effects that coincide with the various treatment modalities. Factors that 
regulate the pain threshold such as anxiety, depression and fatigue must also be 
considered during treatment to provide the best recovery and quality of life for the patient 
(35). If the primary tumor of BrCa patients is discovered before metastasis, surgical 
intervention and chemotherapy continues to be the standard of care. Once invasion of the 
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vasculature occurs, surgical removal of the diseased tissue is no longer a viable option to 
inhibit metastasis to bone. For the BrCa patient who has progressed to bone metastasis, 
treatment is palliative, focusing on controlling pain, inhibiting bone resorption, and 
stopping further metastases.  
 
Palliative Care: 
 Pain is the most common symptom first noticed among patients with bone 
metastasis and becomes worse as time goes on.  The World Health Organization (WHO) 
has developed the 3-step analgesic ladder to provide guidance on the administration of 
analgesic medications to control pain associated with cancer. The ladder starts with non-
steroidal anti-inflammatory drug (NSAIDs) administration and as the disease and 
perceived pain progress, the administration of low-potency and eventually high-potency 
opioids is indicated. Treatment with opioids becomes a significant concern due to the 
risks involved with the increasingly higher doses required to control pain. Other 
pharmaceutical approaches to control pain, increase appetite and improve quality life 
include the use of antidepressants, benzodiazepines, antiepileptics, corticosteroids, 
radiopharmaceuticals and indirectly through the control of resorption through 
bisphosphonates. 
 
Chemotherapy: 
 Chemotherapy has been utilized as an effective treatment option capable of 
remission if BrCa tumor cells are isolated to soft tissue. However, this intervention will 
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not stop the progression of tumor spread once bone metastasis is present. Chemotherapy 
agents are highly cytotoxic and target rapidly differentiating cells. Because chemotherapy 
is systemic, non-cancer cells are affected as well as normal cells, which causes side 
effects such as alopecia, anemia, constipation, diarrhea, fatigue, hemorrhage, 
hyperpigmentation, mucositis, nausea and vomiting, and sexual dysfunction. 
Bisphosphonates: 
 Bisphosphonates are capable of inhibiting resorption through osteoclasts, can 
slow the spread of bone metastases and possibly inhibit extraosseous metastases through 
activation of apoptosis, and inhibition of the metastasis cascade and its ensuing 
angiogenesis (36). Ibandronate is one of the several medications that belongs to the 
bisphosphonate class of drugs and was the sole bisphosphonate used in our study [Figure 
4]. Ibandronate is perhaps one of the most effective tools in the treatment and prevention 
of hypercalcemia, pathologic fracture and bone pain in patients with metastatic BrCa.  
 The mechanism of action behind Ibandronate prevents osteolysis through the 
binding of hydroxyapatite and subsequent uptake by osteoclasts, thereby preventing the 
breakdown of the mineral phase. Two forms of bisphosphonates exist, nitrogenous and 
non-nitrogenous.  The nitrogen in Ibandronate allows the uptake of this medication by 
osteoclasts leading to interference with cytoskeleton formation. This results in the loss of 
the osteoclast ruffled border necessary for the bone seal and thus resorption. Once 
Ibandronate is introduced to the osteoclast, the HMG-CoA reductase pathway is inhibited 
by halting the formation of the metabolites farnesyl and geranylgeraniol (37). These two 
metabolites are essential for cytoskeleton to cell membrane protein attachment. 
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 Ibandronate is also responsible for inducing apoptosis of osteoclasts through the 
action of the ATP analog Apppi (triphosphoric acid 1-adenosin-5′-yl ester 3-[3-
methylbut-3-enyl] ester). This non-functional analog inhibits mitochondrial 
ATP/adenosine diphosphate translocase by competing with functional ATP. The higher 
affinity of Apppi results in a loss of cellular membrane potential and the precipitous 
apoptosis of the osteoclast. In a review of bisphosphonate treatment covering eight 
clinical trials and 1,962 women with advanced stage BrCa and bone metastases, Oral 
Ibandronate demonstrated a 17% (RR 0.83; 95% CI 0.73-0.94, P = 0.004) reduction in 
skeletal-related events following a single regimen (38).  
 Bisphosphonates also have approval for use in the treatment of osteoporosis, 
multiple myeloma, primary hyperparathyroidism, osteogenesis imperfecta and Paget 
disease. The bisphosphonates that are not taken up by bone have a rapid clearance 
making this treatment option one of the safest in the arsenal of treatment modalities for 
BrCa bone metastases patients. When used as an adjunct to chemotherapy, 
bisphosphonate treatment has been shown to have a synergistic effect with a significant 
reduction in skeletal-related events and skeletal morbidity (39).  
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Figure 4: Generations of bisphosphonates 
 have been developed each with the basic structure of two phosphate groups bound to a 
carbon and a variable R-group. The bisphosphonate used in this study is Ibandronate 
(highlighted in red).  
 
Invasive and Minimally Invasive Surgical Intervention: 
 The vertebral collapse in patients with BrCa bone metastases usually occurs 
within the thoracic spine and is considered a pre-terminal event associated with poor 
prognosis. Due to the invasive nature of surgical fixation, this procedure may not be an 
option for all patients. Surgical fixation can prevent pathologic fracture and alleviate or 
prevent pain for patients who can tolerate the procedure. The vertebral collapse that 
involves compression of the spinal cord with associated neurologic loss must be 
evaluated and treated urgently with surgical intervention. Otherwise, permanent paralysis 
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can occur within 24-48 hours (40). Minimally invasive procedures like Balloon 
Kyphoplasty and Vertebroplasty exist as viable treatment options when the complete 
collapse of the vertebral body has not occurred yet, but the risk of fracture is imminent. 
Balloon Kyphoplasty and Vertebroplasty utilize a similar approach to restoring the 
vertebral body by using a cement-like substance that can maintain structural rigidity. 
Both of these treatments provide pain relief by removing compression from the spinal 
cord (41). 
 
Radiotherapy: 
 External beam radiotherapy, nuclide radiotherapy, and radiofrequency ablation 
are all forms of radiotherapy that have all been used successfully to prevent pathological 
fracture and reduce the incidence of pain. External beam radiotherapy (EBRT) is used 
most commonly to relieve pain associated with bone metastases, prevent pathologic 
fracture and has little risk of complications. In a 2007 review of 25 randomized control 
trials using single fraction regimen EBRT to alleviate pain, a complete response was 
observed in 23% of patients and partial pain relief seen in 60-80% of the patients. (42). 
EBRT works through the acceleration of photons that interact with DNA, causing double-
stranded breaks in both normal cells and tumor cells. Normal cells can repair double-
stranded breaks in DNA more readily than tumor cells; this inability to repair breaks halts 
tumor cell replication. Nuclide Radiotherapy uses pharmaceuticals, called 
radiopharmaceuticals, to provide targeted treatment that alleviates pain from bone 
metastases. Sm-153 (Samarium-153) is the most commonly used beta-isotope in the US 
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and is less myelotoxic than previously used beta-isotopes. Sm-153 accumulates in areas 
of the skeleton experiencing high rates of turnover, exposing malignant cells to high 
doses of radiation. The result of radiation exposure to malignant cells is inhibition of cell 
proliferation and thus slowing the progression of skeletal metastases. 
Radiopharmaceuticals do pose a risk for marrow toxicity and myelosuppression, and 
radiotherapy itself inhibits chondrogenesis with an associated decrease in collagen 
protein formation (43), both of which are vital to the process of bone healing. 
Radiofrequency Ablation involves the removal of cancerous tissue within bone while 
staying within the border of the tumor. This process provides pain relief and inhibition of 
tumor progression. Pain alleviation is achieved through the eradication of sensory nerves 
that have been impacted by the cancerous tissue.  
 
Bone Mechanics: 
  The skeleton plays a crucial role in the structural support of bearing the 
aggregation of varying loads placed upon it throughout our daily activities. The 
mechanical behavior of bone is best understood through the observation of bone stiffness 
and strength, which is a function of the total bone mass, geometric distribution of osseous 
tissue and bone material properties.  
 The quantification of total bone mass for cortical bone differs from that of 
trabecular bone due to their respective architecture; cortical bone can be assumed to have 
constant material properties; however, trabecular bone possesses great variability in 
spatial arrangement and is dependent upon location. Cortical bone mass is determined 
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through imaging methods and directly correlates with the cross-sectional area. Due to the 
spatial variability of trabecular bone, the sample mass may be quantified as the volume of 
bone present in the total volume of interest (BV/TV).  Geometric distribution of the 
cortical osseous tissue is determined when cross-sectional area is analyzed in conjunction 
with section modulus and moments of inertia. Trabecular geometric distribution of 
osseous tissue is quantified through analysis of a small trabecular bone sample and 
observing the size and spatial arrangement of trabeculae. Material properties of both 
cortical and trabecular bone are measured through their respective bone mineral content 
(BMC). 
 Mechanical behavior of bone (strength and stiffness) is characterized by the 
individual or combined bending, compression, and tension (uniaxial), and torsional 
loading mechanisms [Figure 3]. These mechanical properties can be determined by 
observation of the resistance of bone to deformation under uniaxial loads (EA), bending 
moments (EI), and torsional loads (GJ). The modulus of elasticity is represented by E 
(Youngs Modulus), A is the cross sectional area, I is the second moment of inertia, G is 
the torsional modulus and J is the polar moment of inertia. When the applied load 
exceeds the inherent elasticity and plasticity of bone, failure occurs through fracture.  
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Figure 5: Mechanical loading modes.  
 Figure from (45). 
 
 Ex vivo mechanical assays reveal changes in rigidity caused by load-deformation 
behavior can be determined through is first revealed on the load-deformation curve 
[Figure 6] by the elastic region, seen as an initial linear progression [Figure 6-A]. During 
this period, bone is in a pre-yield state and stiffness is represented. At this point, bone is 
capable of retreating to its initial form without loss of elasticity if the load is removed. As 
the progression of loading occurs, the pre-yield elastic state is surpassed, and the 
outermost fibers have now advanced to yield a plastic state, representing the strength of 
the bone on the curved portion of the line [Figure 6-B] and signaling that the bone will 
not return to its original form at this point. Strength correlates with energy stored during 
deformation and is visible as the area under the curve. As the area increases, bone 
strength increases. As loading increases further, a post-yield ductile state is achieved 
which will accept additional loading until the ultimate failure is seen [Figure 6-C] and 
loss of LBC is observed through the fracture. 
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Figure 6: Load Deformation Curve. 
Figure from: (44) 
 
Imaging: 
 Accurate prediction of fracture risk from osteolytic lesions requires determination 
of both material and mechanical properties of bone. Previous attempts to determine LBC 
have relied upon interpretation of two-dimensional radiographs for a given cross section 
of bone. Evaluation of LBC by this method has consistently low accuracy, can lead to 
unnecessary surgical stabilization, and is unable to provide tracking of disease 
progression and treatment. CTRA uses composite beam theory in conjunction with data 
obtained from serial transaxial CT images (QCT) to yield a noninvasive approach for 
prediction of a whole bone fracture threshold. CTRA has been shown to predict fracture 
risk threshold with 100% sensitivity and 90% specificity.  
 Subjective prediction of fracture risk using two-dimensional radiographs has 
historically been dependent upon two guidelines: 1) defect greater than 2.5cm in diameter 
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should be considered at risk and 2) greater than 50% cortical destruction is a candidate 
for prophylactic surgical stabilization.  
 Whole bone structural rigidity interpreted from serial transaxial CT images is 
analyzed through uniaxial loads (EA), bending moments (EI), torsional loads (GJ) and 
bone mineral density (BMD) to yield a three-dimensional approach in evaluation of 
changes from BrCa induced osteolytic lesions. With the use of Hydroxyapatite (HA) 
phantoms containing three chambers of 0, 500, and 1000g cm-3 HA density, conversion 
of the x-ray attenuation for each pixel is performed to determine BMD and to compare 
cases from alternate imaging sites. Perpendicular alignment of the CT images to the 
neutral axis of the bone of interest ensures that true transaxial images are retrieved. The 
standard HA calibration phantom is used to convert CT HU to BMD. As previously 
discussed, EA, EI, and GJ calculations determine structural rigidity and thus LBC when 
BMD is considered. 
 In order to account for the differences in trabecular and cortical bone architecture, 
the elastic modulus for each is determined. Derivation of trabecular elasticity modulus 
can be obtained through the Rice et al. relationship: 
E = 0.82ρ2 + 0.17 …..[1]  
For cortical bone, the Snyder et al. relationship is used: 
E = 21.91ρ2 – 23.5 …..[2] 
Based upon the assumption that a transition between cortical and trabecular bone occurs 
at an apparent density of 1.1g cm-3, EA, EI, and GJ are calculated as follows: 
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EA = ∫ E(ρ)da …..[3] 
EI = ∫ E(ρ)y2da …..[4] 
GJ = ∫ G(ρ)(x2 + y2)da …..[5] 
where x and y are the distances to the neutral axis of the transaxial cross section, and da 
is the pixel area [Figure 7]. 
 
Figure 7: Calculation of structural rigidity.EA, EI, and GJ extrapolated from transaxial 
CT images. Normalization is achieved through comparison of osteolytic and lesion-free 
bone, (da) = pixel size. Incidence of fracture predicted when EA, EI, or GJ ≤ 65% of 
contralateral aspect. 
 
Rodent Model: 
 The heterogeneity of the clinical population of patients with skeletal metastases 
with respect to the extent and location of metastatic disease and the variability in anti-
  31 
cancer treatment protocols make it impossible to address the effect of bone remodeling 
and treatment on tumor growth and fracture risk in a controlled fashion. Therefore, our 
study was conducted in an animal model of osteolytic defects where more control over 
the study design parameters could be maintained than would be ethically or logistically 
possible in a human study. 
 Animal models are important tools to investigate the pathogenesis and treatment 
of skeletal metastasis as they occur in humans. Since spontaneous skeletal metastasis are 
rare in animals, most models require experimental manipulation, such as direct injection 
or implantation of neoplastic cells into bones (45-53), the left ventricle of the heart (53-
56) or the lungs of experimental animals, such as rats or mice.  A disadvantage of the 
systemic approach is that bone lesions tend to occur throughout the skeleton in non-
reproducible locations making comparative analysis of tumor activity at a specific site 
difficult. Additionally, animals may also die prematurely from the increased tumor load. 
 A human breast carcinoma cell line, MDA-MB-231, has been used in nude 
murine models, largely to examine the biology of skeletal metastases (45, 57-60).  Direct 
inoculation of the cells into the femoral medullary canal can create reproducible site-
specific lesions. Unlike systemic inoculation, this method tends to reduce the number of 
metastatic tumors throughout the body, thus reducing the tumor load and allowing animal 
subjects to live with the disease for a longer period of time. While the tumor is not truly 
metastatic, it creates a reproducible model of BrCa tumor activity within an osseous 
environment that will act as a model for similar osteolytic activity in metastatic cancers.
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MATERIALS AND METHODS 
 
A total of 40 eight-week old virgin female nude (NIHRNU-M) rats (100-150g) 
were obtained from the Charles River Laboratories. Ten of the rats were randomly 
assigned to the CONTROL group to undergo a sham surgery in which no cancer cells 
were used. The other 30 rats were chosen to be inoculated with MDA-MB-231 human 
breast cancer cells (courtesy of Dr. Theresa Guise, University of Virginia) and then 
divided into the Cancer (10 rats), Ibandronate (10 rats), and Paclitaxel (10 rats) groups 
[Figure 8]. The contralateral, non-surgical limb served as the internal control for each 
specimen, which effectively eliminated biological variation between animals as this was 
an intra-animal comparison. Animal experimental protocols were approved by Beth Israel 
Deaconess Institutional Animal Care and Use Committee. 
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subcutaneous injection] 
MDA-MB-231 human breast  
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5
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0 
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1 2 3 4 5 6 7 
Time 
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X 
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Figure 8: An outline of the study presented. 
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Surgical inoculation: 
The experimental design requires a simulated metastatic lesion in a reproducible 
location. For this reason, a method of femoral intramedullary inoculation was used to 
create site specific lesions. Unlike systemic inoculation, this method tends to reduce the 
number of metastatic tumors throughout the body thus reducing tumor burden and 
allowing the animals to live with the disease for a longer period of time.  
Utilizing surgical aseptic conditions, the procedure was performed in a sterile 
field using sterile instruments. Rats were anesthetized by an intraperitoneal injection of 
Ketamine (75mg/kg) and Xylazine (5mg/kg). Hind limbs were then scrubbed with 
betadine and alcohol before being secured to the surgery table. A small incision was 
made on the medial surface of the knee taking caution to cut through the skin only. 
Muscle tissue was then divided using the blunt tips of scissors to minimize bleeding and 
trauma until the medial condyle of the femur was visible. Under fluoroscopic guidance, a 
dental drill was used to create a portal through the cortex of the medial condyle at 
approximately a 45o elevation from the shaft of the femur. A needle was then used to 
extend the portal into the medullary canal; proper entrance was confirmed by visible 
bleeding within the portal and fluoroscopic images showing the needle in the canal. MDA 
cancer cells (2 x 105 cells suspended in 50 μL of 0.9% saline) were then injected into the 
canal. Control animals received an injection of equal volume saline only. The incision 
was then closed using surgical staples and coated with triple-antibiotic ointment. Post-
operative care included close observation of anesthetized animals while in cages placed 
under heat lamps to maintain body temperature until they regained full consciousness and 
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were able to move freely about the cages. All rats received 0.3mg/kg doses of 
buprenorphine hydrochloride (Bupranex) every 6 hours for 48 hours post-op to minimize 
resultant pain. 
 
Weekly Imaging and Image Analysis: 
Every seven days, animals were anesthetized and imaged with DXA, contact 
radiography, and QCT imaging. The animals were observed for loss of mobility, lethargy, 
and weight loss.  
 
Dual X-Ray Absorptiometry: 
DXA scans were obtained using the Lunar PIXImus2 (GE Healthcare, Waukesha, 
Wisconsin, USA) to monitor bone mineral density and bone mineral content. Due to the 
size of the rats, this required separate scans of each femur. The PIXImus software was 
used to calculate BMC and BMD at two anatomical locations (the metaphyseal region 
and the diaphyseal region) [Figure 9].  
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Figure 9: DXA Analysis- Using PIXImus software. Two anatomical regions of interest 
are specified. BMC and BMD are calculated for each region. 
 
X-Ray: 
Anterior-Posterior biplanar radiographic images were taken using a Faxitron X-
ray device (HP Faxitron Cabinet X-ray system, Model 43855A, McMinnville, OR) on 
Kodak X-OMAT film. These films were blinded and analyzed by two independent 
observers using a four point categorical scale [Figure 10]. A score of 1 was given to a 
film in which no lesions were visible. A score of 2 was given to a film in which a small 
lesion (lesion was <50% the diameter of the site) was visible. A score of 3 was given to a 
film in which a large lesion (lesion was >50% the diameter of the site) was visible. A 
score of 4 was given to any film in which fracture (misalignment of the bone segments) 
was visible. All scores were based on the largest lesion visible. This scoring system was 
devised in correlation with current clinical criteria used to evaluate lesions that are 
considered at significant risk of fracture (those lesions >50% the diameter of the site) (61-
65). Scores from the two observers were then averaged.  
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Figure 10: Categorical scale for radiographic film analysis. 
 
Quantitative Computed Tomography:  
The QCT Research SA+ (Stratec, Pforzheim, Germany) was used to obtain QCT 
images of the distal femora. Animal subjects were restrained in a fashion similar to 
human anatomical position (simulated bipedal orientation of the femora) to create slices 
perpendicular to the femora. Serial transaxial slices with 100μm in-plane voxel size and 
490μm slice thickness were taken covering an area of approximately 10mm proximal to 
the growth plate (metaphyseal and distal diaphyseal regions).  
Slice image files were converted from the proprietary image format (.MOI) to a 
common CT format (.DICOM) using Analyze Software (Mayo Clinic, Rochester, 
Minnesota, USA). Analyze Software was then used to segment and register the three-
dimensional reconstructions of each femur. Segmentation is the process by which the 
femur is separated from adjacent soft tissue and the patella is removed from the image 
sequence. This removes any non-osseous tissue from the image sequence that may affect 
the image analysis process and prevent the patellae from contributing to rigidity 
calculations of the femur. Registration is the process of orienting the right and left femora 
in the same spatial orientation; this involves flipping one image sequence and then 
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adjusting pitch, yaw, translation, and rotation. This eliminates the element of spatial 
orientation from confounding the calculations performed in the image analysis process 
and enables proper alignment of homologous slices from each limb [Figure 11]. 
 
Figure 11: Homologous slices of right and left femora where the lytic lesion is visible. 
Rigidity values calculated from each slice was normalized by the non-surgical limb to 
account for biological variation and serve as the intra-animal control. 
 
An in-house developed software package using NIH ImageJ was needed to 
calculate structural rigidity values for each individual slice [Figure 12]. This image 
analysis software was calibrated to assign the appropriate density value to the attenuation 
coefficient, or grey-scale value, of each pixel. This calibration is made possible by 
scanning hydroxyapatite phantoms [Appendix B] of known density and plotting 
attenuation coefficients against density values. Although bone is composed of mineral, 
organic matrix and water, CT primarily images the bone mineral component. Therefore, 
the density measured by QCT approximates the density of the mineral phase, or the ash 
density, ρash. In order to use empirically derived density-to-modulus relationships, the 
density must be adjusted by the mass ash fraction, fash, to calculate the apparent bone 
density, ρapp (the density of the combined mineral and organic phase of bone): 
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ρapp  =  ρash/ fash 
where fash is 0.66 as reported by Cowin (66). 
 
These pixel density values were then converted to elastic modulus to describe the 
material present in each pixel using species-specific empirically derived relationships. 
These empirically derived constitutive relationships are: 
Human:  
E(ρ)trabecular = 0.82ρ
2 + 0.07           (67) 
E(ρ)cortical = 21.91ρ – 23.5             (68) 
Rat:  
E(ρ)trabecular = 4.43ρ – 16.03         (69)   
E(ρ)cortical = 3.78ρ – 11.71         (69) 
 
The elastic modulus is the intrinsic stiffness of a material and is defined by the 
slope of the linear region of the load-deformation curve. This modulus-weighted pixel 
value was used in the calculations of axial rigidity (EA), bending rigidity (EI), and 
torsional rigidity (GJ). The location of each pixel, the pixel area, and the modulus value 
are used to calculate a value which is then summed for all pixels.  
Axial Rigidity:  EA = Σ Ei(ρapp) da 
Bending Rigidity:  EI = Σ {Ei(ρapp) xi
2}da 
Torsional Rigidity:  GJ = Σ{Gi(ρapp)((xi)
2 + (yi)
2)}da 
  39 
 
Figure 12: Modulus-weighted pixel is summation with its distance from the centroid in 
the calculations of EA, EI and GJ. Where E is the modulus of elasticity of pixel, i, with 
density, ρapp, da is the area of the pixel, xi and yi are the distances to the coordinates of 
the modulus-weighted centroid. 
 
where E is the modulus of elasticity of pixel, i, with density, ρapp, da is the area of the 
pixel, xi and yi are the distances to the coordinates of the modulus-weighted centroid.  By 
combining material information (the modulus of the pixel) with geometric information 
(relation to the centroid), these calculations account for both elements which contribute to 
the strength of bone.  Rigidity values were normalized by the homologous slice of the 
normal contralateral femur thus expressing all data as relative change from the 
contralateral. A reference value of 1.0 indicates equal rigidity values in homologous 
slices. This normalization was performed to account for biological variation and to utilize 
the contralateral limb as the intra-animal control. For each specimen, the cross-section 
with the minimum predicted rigidity is assumed to be the site of failure initiation.
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Statistical Analyses: 
 Repeated analyses of variance (ANOVA) was processed through SPSS v22 
statistical software, in order to assess the intergroup differences between the treatments.  
Kappa testing was applied to assess differences between the inter-observer scores.  
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RESULTS 
 
DXA based diaphyseal bone mineral density values, normalized by the values 
from the homologous region of the contralateral side, were not different between the four 
groups over time (P = 0.144) as assessed by repeated measures analysis of variance 
(ANOVA).  Similarly, DXA based metaphyseal bone mineral density values were not 
different between the four groups over time (P = 0.656) [Figure 13 A and B]. 
 
Figure 13: A Diaphyseal BMD of femurs normalized by the contralateral side; and B) 
Metaphyseal BMD of femurs normalized by the contralateral side 
 
Radiography based analysis of images from the lesions during the course of the 
study indicated no differences between the 4 groups over time (P = 0.891). Figures 14 A, 
B and demonstrate the X-ray scores for Cancer, Paclitaxel and Ibandronate groups 
respectively.  Additionally, Figure 15 provides an average X-ray scoring snapshot of the 
study as done so by two independent observers. Inter-operator Kappa testing indicated 
significant differences between the two independent observers’ scores (P = 0.001). 
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Figure 14: X-ray based scores:A) Cancer group; B) Paclitaxel group; and C) Ibandronate 
group. 
 
Figure 15: Average X-ray scores for all groups over time. 
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Axial, bending, and torsional rigidities of the affected limbs were normalized by 
the rigidity results of the homologous regions of the unaffected contralateral limbs. This 
provided a percent change (negative referring to loss of rigidity and positive referring to 
gain in rigidity) in rigidity values from baseline, as a preferred mode of communication 
of results by orthopedic oncologists. The normalized CTRA results indicated significant 
changes in rigidity values across times points 4 and onward between control and other 
groups (Cancer, Paclitaxel, and Ibandronate). These results are highlighted in Table 2 
with P values from repeated measure ANOVA studies with group as fixed factor and time 
as repeat factor using estimated margin means. These results are based on 20 specimens 
(5 per group), as the analysis of the images is rather time consuming.  The remaining 
results will be available within the next few weeks. Furthermore, animal specific CTRA  
Group 1 Group 2 4 5 6 7 8
Control Cancer 0.045 0.090 0.007 0.046
Control Paclitaxel 0.042 0.022 0.006
Control Ibandronate 0.048 0.042 0.021
Group 1 Group 2 4 5 6 7 8
Control Cancer 0.055 0.007 0.015
Control Paclitaxel 0.031 0.008 0.048 0.021
Control Ibandronate 0.028 0.052
Group 1 Group 2 4 5 6 7 8
Control Cancer 0.0001
Control Paclitaxel 0.0001 0.054 0.032
Control Ibandronate 0.001 0.028 0.030
Time (wks)
Time (wks)
Time (wks)
E
A
E
I
G
J
 Table 1: P values for CTRA results between groups over time (solid blocks indicate no significance). 
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 Results were generated for all animals over time. This provided a useful snapshot 
of changes in rigidity values over time, as animal were subjected to any treatment. Figure 
16 highlights 4 representative animals from the study, where constant CTRA results were 
reported for the control animal (A); whereas the results in the cancer animal indicted 
reduced rigidity from week 4 to 7, followed by an increased drop in rigidity at week 8 
(B). The animal from paclitaxel group experienced loss of rigidity in the femur, due to 
the lesion; however, by week 8, rigidity results were restored to baseline values (C). 
Finally, the 
animal in 
the Paclitaxel group experienced  a larger loss of rigidity in the femur, due to the lesion 
size, between weeks 4 to 7, when compared to the paclitaxel animal; however it also 
experience an increase in rigidity at week 8.  
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Figure 16: CTRA Results 
 from representative animals from Control (A), Cancer (B), Paclitaxel (C), and 
Ibandronate (D) groups. 
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DISCUSSION 
 
 CTRA results indicted significant changes in rigidity values over time, either in 
response to increase in tumor burden due to lack of treatment or decrease in tumor burden 
in response to treatment options. We used normalized rigidity indices to work with 
changes in rigidities as opposed to absolute rigidity values, which are more difficult to 
visualize. At any given time point, at least one of the rigidity indices was significant in 
terms of change from the control group. This is significant as none of the other modalities 
were able to provide significant changes over time between the control and the other 
groups. The CTRA results reflect data from 20 specimens only. Upon completion of the 
study, we’ll be able to compare changes across different groups over time. 
 Plotting of CTRA indices for individual animals provided an easy means to 
follow changes in the rigidity of the animal in response to host bone, lesion, and 
treatment interactions. The control group figure (Figure 16A) indicated little changes 
over time in rigidity values, as expected.  However, the cancer group (Figure 16B) 
indicated reduction in rigidity over time, where the reduction was stable over the first 
three weeks; however, it began to increase at week 8 to 60% below baseline values. This 
animal is at a great risk for fracture, and in fact it suffered a femur fracture at week 8 
prior to euthanasia.  
Both treatment options seems to help increase the rigidity of the bones towards 
the end of the study. In both Paclitaxel and Ibandronate cases, increases of up to 30% in 
rigidity indices were observed in the animals. The animal in the Ibandronate group had 
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suffered from a much larger reduction in rigidity than the animal in the Paclitaxel group, 
where the rigidity values were back to baseline levels by week 8. 
 Both DXA based BMD and X-ray based radiographic techniques failed to show 
differences between groups over time. Not surprisingly, the diaphyseal BMD values were 
not different across groups, as they were very close to the baseline. Given the higher rate 
of metabolic change in trabecular bones, the metaphyseal BMD values were more 
sensitive to change, especially in both treatment group; however, they failed to reach 
significance. 
 In our study, we developed an in-house four-point categorical scale similar to the 
Mirels criteria that was applicable to an animal study. A critical value of 2 (lesion <50% 
diameter of the bone) was chosen as the predictive fracture threshold. Any animal that 
scored greater than 3 (lesion size >50% diameter by at least one observer) was predicted 
to fracture. Radiographic scoring was inconsistent between the two independent 
observers and failed to indicate changes over time between groups. The former is an issue 
widely observed in clinical settings, where multiple physicians will arrive at different 
scores upon reviewing the same radiograph.   The Mirels method for analyzing bone 
metastatic lesions is applicable to the human patient populace only and uses site, pain, 
lesion type and size as a method for determining fracture risk.  A score above 7 suggests 
irradiation, while a score above 9 is deemed to be a candidate for surgical stabilization. 
Although the Mirels method of predicting fracture risk has been a valuable tool in the 
past, its methodology has been shown to be vulnerable to the subjective interpretation of 
pain and lesion type (70). Mirels method has been shown to have only 35% specificity 
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with variations amongst different anatomical locations, leading to 2/3 of surgical cases 
unnecessarily undergoing surgery and associated complications (71). In a recent study by 
Nazarian et al., they found the Mirels criteria were not under equal consideration in 
common practice, but instead pain and lesion type were more heavily weighted (70). Pain 
has been shown to be unreliable as a predictive method for fracture risk (72). When strict 
adherence to Mirels criteria was in practice, Nazarian et al. observed that 64% of patients 
were recommended for surgical fixation. If pain and lesion type influenced surgical case 
more so than the other criteria, only 43% of the same cases were considered for surgical 
fixation. 
 We aimed to demonstrate the most accurate method to assess changes in bone 
strength, hence pathologic fracture risk, resultant from skeletal metastasis. Through the 
use of CTRA we were able to pick a threshold for fracture risk with 100% sensitivity and 
90% specificity in a multi-center study, which is considerably more precise than Mirels 
(71% sensitivity and 50% specificity) (70), the current clinical standard for prediction of 
fracture risk. 
 Limitations of our study are in the limited number of animals used for the study 
and the fact that not all the available data could be analyzed due to time constraints. In 
order to provide a better assessment of the ability of the CTRA technique to predict 
fracture, Receiver Operator Characteristic curves must be constructed to assess thresholds 
for fracture for each imaging modality. At that point their sensitivities and specificities 
must be compared to provide a definitive assessment of the capability of each modality. 
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 This is the first study that evaluates the impact of CTRA results on fracture 
prediction in animals with metastatic lesions in a controlled setting. The results of this 
study further validates that the existing gap between clinical guidelines and physician’s 
recommendations in the decision making process for the selection of surgical or non-
surgical treatment must be narrowed by more advanced prognostic tools such as CTRA. 
Our ultimate goal is to expand this study to include additional treatment options and 
larger group size to evaluate the value of CTRA in a large animal cohort subjected to 
specific treatment options over time. 
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